PMID- 31501367
OWN - NLM
STAT- MEDLINE
DCOM- 20190912
LR  - 20190912
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 46
IP  - 8
DP  - 2019 Aug
TI  - [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable 
      Pancreatic Cancer].
PG  - 1259-1263
AB  - We retrospectively analyzed adverse effects(AEs), overall survival(OS), and 
      progression-free survival(PFS)in 15 consecutive patients treated with FOLFIRINOX 
      as the first-line treatment for recurrent or unresectable pancreatic ductal 
      adenocarcinoma( PDAC)between February 2014 and December 2017 in our hospital. 
      Eleven patients were treated for unresectable PDAC with distant metastases(UR-M), 
      and 4 were treated for locally advanced unresectable PDAC(UR-LA). The median age 
      was 56(range: 40-75)years. Nine patients were male, and 6 were female. The 
      performance status was 0 or 1 in all patients. Tumors were located in the 
      pancreas head in 8 cases and in the body-tail in 7 cases. Grade 5 AEs were 
      observed in 1 case in which liver abscess causing sepsis resulted in mortality. 
      The response rate was 20.0%, and the disease control rate was 66.7%. Two patients 
      underwent conversion surgery after FOLFIRINOX treatment. Seven patients received 
      a nab-paclitaxel plus gemcitabine regimen as second-line treatment. The median OS 
      and PFS were 17.0 and 8.4 months, respectively, and the 1-year survival rate was 
      66.7%. FOLFIRINOX for recurrent and unresectable PDAC showed relatively good 
      tumor control. However, strict attention is required for severe AEs. Conversion 
      surgery might be effective in patients who are good responders even if they have 
      metastatic disease.
FAU - Tsujie, Masanori
AU  - Tsujie M
AD  - Dept. of Surgery, Kindai University Nara Hospital.
FAU - Fumita, Soichi
AU  - Fumita S
FAU - Ishikawa, Hajime
AU  - Ishikawa H
FAU - Kitani, Kotaro
AU  - Kitani K
FAU - Satoi, Shumpei
AU  - Satoi S
FAU - Fukuda, Shuichi
AU  - Fukuda S
FAU - Manabe, Hironobu
AU  - Manabe H
FAU - Akashi, Yusaku
AU  - Akashi Y
FAU - Wakasa, Tomoko
AU  - Wakasa T
FAU - Shiono, Hiroyuki
AU  - Shiono H
FAU - Tamura, Takao
AU  - Tamura T
FAU - Yukawa, Masao
AU  - Yukawa M
FAU - Inoue, Masatoshi
AU  - Inoue M
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Pancreatic Ductal
MH  - Female
MH  - Fluorouracil
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Retrospective Studies
EDAT- 2019/09/11 06:00
MHDA- 2019/09/13 06:00
CRDT- 2019/09/11 06:00
PHST- 2019/09/11 06:00 [entrez]
PHST- 2019/09/11 06:00 [pubmed]
PHST- 2019/09/13 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2019 Aug;46(8):1259-1263.